DOCSLIB.ORG

HA Drug Formulary External List V12 2 161008 (Dated 161006).Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HA Drug Formulary External List V12 2 161008 (Dated 161006).Xlsx HOSPITAL AUTHORITY DRUG FORMULARY (v12.2 - w.e.f.8 Oct 2016) new drugs listed highlighted in yellow color (1) The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand. (2) Some drugs may appear in more than one category due to different formulations and/or indications. (3) The "Special" drugs will be prescribed as clinically indicated based on the specified indications. (4) Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed in the HA Drug Formulary. Self-financied item Self-financied item BNF General Drugs Special Drugs With Safety Net Without Safety Net 6 ENDOCRINE SYSTEM 內分泌系統藥物 6.1 DRUGS USED IN DIABETES DEXTROSE ACARBOSE EXENATIDE GLIBENCLAMIDE ALOGLIPTIN LIRAGLUTIDE GLICLAZIDE ALOGLIPTIN+PIOGLITAZONE LIXISENATIDE GLIMEPIRIDE BIPHASIC INSULIN ASPART GLIPIZIDE BIPHASIC INSULIN LISPRO GLUCAGON DAPAGLIFLOZIN INSULIN HUMAN (HUMULIN/ MIXTARD) INSULIN ASPART HUMAN INSULIN ISOPHANE HUMAN INSULIN DETEMIR INSULIN NEUTRAL HUMAN INSULIN GLARGINE METFORMIN INSULIN GLULISINE INSULIN LISPRO HUMAN LINAGLIPTIN LINAGLIPTIN+METFORMIN METFORMIN PIOGLITAZONE PIOGLITAZONE + METFORMIN SAXAGLIPTIN SITAGLIPTIN SITAGLIPTIN+METFORMIN VILDAGLIPTIN VILDAGLIPTIN + METFORMIN 6.2 THYROID AND ANTITHYROID DRUGS CARBIMAZOLE IODINE METHIMAZOLE POTASSIUM IODIDE PROPYL THIOURACIL THYROXINE TIRATRICOL 6.3 CORTICOSTEROIDS BETAMETHASONE DEXAMETHASONE FLUDROCORTISONE HYDROCORTISONE METHYLPREDNISOLONE PREDNISOLONE TRIAMCINOLONE ACETONIDE 6.4 SEX HORMONES MEDROXYPROGESTERONE ACETATE ACTIVELLE (OR EQUIV) PROGESTERONE (VAGINAL) NANDROLONE CYPROTERONE TIBOLONE NORETHISTERONE DIENOGEST OESTROGENS CONJUGATED DYDROGESTERONE SUSTANON (OR EQUIV) ESTRADIOL TESTOSTERONE (TOPICAL) FEMOSTON (OR EQUIV) TESTOSTERONE ENANTHATE FINASTERIDE (PROSCAR) (OR EQUIV) TESTOSTERONE UNDECANOATE KLIOGEST (OR EQUIV) NOVOFEM (OR EQUIV) OESTRADIOL OESTROGEL (OR EQUIV) OESTROGENS CONJUGATED PREMELLE (OR EQUIV) PROGESTERONE PROGESTERONE (VAGINAL) RALOXIFENE TRISEQUENS (OR EQUIV) ULIPRISTAL (ESMYA) Self-financied item Self-financied item BNF General Drugs Special Drugs With Safety Net Without Safety Net HYPOTHALAMIC AND PITUITARY 6.5 HORMONES AND ANTI-OESTROGENS CLOMIPHENE DESMOPRESSIN (DDAVP) SOMATROPIN FOLLITROPIN ALFA CORTICORELIN (HUMAN) HUMAN CHORIONIC GONADOTROPHIN FOLLITROPIN BETA HUMAN CHORIONIC DESMOPRESSIN (DDAVP) MENOTROPHIN GONADOTROPHIN PROTIRELIN SOMATROPIN MENOTROPHIN TERLIPRESSIN THYROTROPIN ALFA VASOPRESSIN 6.6 DRUGS AFFECTING BONE METABOLISM ALENDRONATE + ALENDRONATE CHOLECALCIFEROL CLODRONATE DENOSUMAB (PROLIA) DENOSUMAB (PROLIA) DENOSUMAB (XGEVA) IBANDRONIC ACID IBANDRONIC ACID (BONVIVA) (BONDRONAT) ZOLEDRONIC ACID PAMIDRONATE (ZOMETA) RISEDRONATE SALCATONIN SALCATONIN (NASAL) STRONTIUM RANELATE TERIPARATIDE ZOLEDRONIC ACID (ACLASTA) ZOLEDRONIC ACID (ZOMETA) 6.7 OTHER ENDOCRINE DRUGS BROMOCRIPTINE CABERGOLINE CETRORELIX DANAZOL QUINAGOLIDE GANIRELIX METYRAPONE.
Load more

Recommended publications
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • Thyroid Hormone Misuse and Abuse
    Endocrine (2019) 66:79–86 https://doi.org/10.1007/s12020-019-02045-1 REVIEW Thyroid hormone misuse and abuse Victor J. Bernet 1,2 Received: 11 June 2019 / Accepted: 2 August 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects. Keywords Thyrotoxicosis ● Thyroid hormone abuse ● Thyroid hormone misuse ● Factitious thyrotoxicosis ● Supplements ● 1234567890();,: 1234567890();,: Analogs Overdose Thyroid hormone misuse and abuse secondary to exogenous TH ingestion that may be unin- tentional or purposeful such as in some cases of Munch- Almost any substance that impacts body physiology and ausen syndrome. Instances of TH misuse can be associated function is at risk for misuse or frank abuse, usually in the with the development of significant side effects. There are misgiven belief that the particular agent whether it be a other instances of chronic, low-grade over treatment with herb, supplement, medication, or hormone has healing TH, which occur for various misreasoning such as weight properties beyond that of which it actually possesses.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Corticorelin Acetate, a Synthetic Corticotropin-Releasing Factor with Preclinical Antitumor Activity, Alone and with Bevacizumab, Against Human Brain Tumor Models
    ANTICANCER RESEARCH 30: 5037-5042 (2010) Corticorelin Acetate, a Synthetic Corticotropin-releasing Factor with Preclinical Antitumor Activity, alone and with Bevacizumab, against Human Brain Tumor Models IDOIA GAMEZ1, ROBERT P. RYAN1 and STEPHEN T. KEIR2 1Celtic Pharmaceutical Development Services America, Inc., New York, NY 10022, U.S.A.; 2The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC 27710, U.S.A. Abstract. Background: Corticorelin acetate (CrA) is a brain tumors. The cause of PBE is believed to result in part synthetic form of corticotropin-releasing factor that is from the leakage of edematous brain tumor fluid from currently undergoing clinical trials in the treatment of abnormal tumor vasculature into the surrounding tissue (1, peritumoral brain edema (PBE). This study preclinically 2). The mechanism(s) of action by which CrA exerts its investigated its potential as an antitumor agent against beneficial effect in the therapy of PBE has not been human brain tumor xenografts. Materials and Methods: The elucidated, but two factors appear to be relevant: decreased in vivo efficacy of CrA as a single agent and in combination vascular leakage and preserved integrity of the endothelial with the antiangiogenic agent, bevacizumab, was examined cells, which ultimately helps to maintain the blood-brain in three different patient-derived human brain tumor barrier (3, 4). xenografts implanted orthotopically (intracranially) or CrA appears to mediate its activity through two subtypes subcutaneously in athymic mice. Results: CrA significantly of G-protein coupled receptors: CRF receptor-1 (CRFR1) increased the lifespan of mice implanted orthotopically with and CRF receptor-2 (CRFR2) (5). These CRFRs are widely two different pediatric brain tumor xenograft models.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Preferred Drug List (Formulary)
    January 2020 Molina Healthcare of Michigan Preferred Drug List (Formulary) 1 Molina Healthcare of Michigan Preferred Drug List (Formulary) (01/01/2020) INTRODUCTION ..........................................................................................................................................................................................................................................5 PREFACE .....................................................................................................................................................................................................................................................5 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ..........................................................................................................................................................................5 DRUG LIST PRODUCT DESCRIPTIONS ...................................................................................................................................................................................................5 GENERIC SUBSTITUTION ..........................................................................................................................................................................................................................5 PLAN DESIGN .............................................................................................................................................................................................................................................6
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016
    Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 0054T Bone Srgry Cmptr Fluor Image NA $84.39 0055T Bone Srgry Cmptr Ct/Mri Imag NA $84.39 0178T 64 Lead Ecg W/I&R M M 0179T 64 Lead Ecg W/Tracing M M 0180T 64 Lead Ecg W/I&R Only M M 0190T Place Intraoc Radiation Src M M 0191T Insert Ant Segment Drain Int $379.27 $379.27 0195T Prescrl Fuse W/O Instr L5/S1 NA M 0196T Prescrl Fuse W/O Instr L4/L5 NA M 0198T Ocular Blood Flow Measure M M 0200T Perq Sacral Augmt Unilat Inj $987.92 $243.46 0201T Perq Sacral Augmt Bilat Inj $553.69 $120.64 0202T Post Vert Arthrplst 1 Lumbar $4,128.40 $288.24 0205T Inirs Each Vessel Add-On NA $63.19 0206T Cptr Dbs Alys Car Elec Dta $14.66 $14.66 0207T Clear Eyelid Gland W/Heat $136.47 $68.53 0208T Audiometry Air Only $17.43 NA 0209T Audiometry Air & Bone $20.80 NA 0210T Speech Audiometry Threshold $13.07 NA 0211T Speech Audiom Thresh & Recog $20.80 NA 0212T Compre Audiometry Evaluation $21.00 $18.42 0213T Njx Paravert W/Us Cer/Thor $107.57 $60.82 0214T Njx Paravert W/Us Cer/Thor $53.09 $34.47 0215T Njx Paravert W/Us Cer/Thor $53.29 $34.87 0216T Njx Paravert W/Us Lumb/Sac $97.66 $52.10 0217T Njx Paravert W/Us Lumb/Sac $48.93 $29.72 0218T Njx Paravert W/Us Lumb/Sac $49.13 $30.11 0219T Plmt Post Facet Implt Cerv $238.91 $129.56 0220T Plmt Post Facet Implt Thor $238.91 $129.56 0221T Plmt Post Facet Implt Lumb $236.14 $127.77 0222T Plmt Post Facet Implt Addl
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Triiodothyroacetic Acid in Health and Disease
    234 2 S GROENEWEG and others Triac in health and disease 234:2 R99–R121 Review Triiodothyroacetic acid in health and disease Correspondence Stefan Groeneweg, Robin P Peeters, Theo J Visser and W Edward Visser should be addressed Department of Internal Medicine and Academic Center for Thyroid Diseases, Erasmus University to W E Visser Medical Center, Rotterdam, The Netherlands Email [email protected] Abstract Thyroid hormone (TH) is crucial for development and metabolism of many tissues. The Key Words physiological relevance and therapeutic potential of TH analogs have gained attention in f thyroid hormone the field for many years. In particular, the relevance and use of 3,3′,5-triiodothyroacetic f resistance to thyroid hormone (RTH) acid (Triac, TA3) has been explored over the last decades. Although TA3 closely resembles f thyroid hormone analog the bioactive hormone T3, differences in transmembrane transport and receptor isoform- f thyroacetic acid specific transcriptional activation potency exist. For these reasons, the application of TA3 derivatives as a treatment for resistance to TH (RTH) syndromes, especially MCT8 deficiency, is topic of f Triac ongoing research. This review is a summary of all currently available literature about the f TA3 formation, metabolism, action and therapeutic applications of TA3. Endocrinology Journal of Endocrinology of (2017) 234, R99–R121 Journal Introduction Thyroid hormone (TH) is crucial for the development and The deiodinases (D1–3) importantly regulate the bio- metabolism of many tissues. Thyroid stimulating hormone availability of T3 in targets cells, while TH is also (TSH) controls the production and secretion of TH by the metabolized by glucuronidation and sulfation, which thyroid gland, which predominantly produces the pro- enhance biliary excretion (Engler & Burger 1984, Burger hormone thyroxine (T4) and to a lesser extent the bioactive 1986, Visser 1996).
    [Show full text]